Cargando…

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Human glutaminyl cyclase (hQC) is drawing considerable attention and emerging as a potential druggable target for Alzheimer's disease (AD) due to its close involvement in the pathology of AD via the post-translational pyroglutamate modification of amyloid-β. A recent phase 2a study has shown pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Daoyuan, Chen, Qingxiu, Qin, Xiaofei, Tong, Peipei, Peng, Liping, Zhang, Tao, Xia, Chunli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Aging Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435661/ https://www.ncbi.nlm.nih.gov/pubmed/37600512 http://dx.doi.org/10.3389/fnagi.2023.1209863

Ejemplares similares

Soluble Variants of Human Recombinant Glutaminyl Cyclase
por: Castaldo, Cristiana, et al.
Publicado: (2013)

In vitro and in silico determination of glutaminyl cyclase inhibitors
por: Tran, Phuong-Thao, et al.
Publicado: (2019)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors
por: Hielscher-Michael, Stephanie, et al.
Publicado: (2016)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells
por: Shang, Qi, et al.
Publicado: (2022)

Disturbed Ca(2+) Homeostasis Increases Glutaminyl Cyclase Expression; Connecting Two Early Pathogenic Events in Alzheimer’s Disease In Vitro
por: De Kimpe, Line, et al.
Publicado: (2012)

The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions
por: Cynis, Holger, et al.
Publicado: (2011)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes
por: Wu, Vincent W., et al.
Publicado: (2017)

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2021)

The Bacteroidetes Q-rule and glutaminyl cyclase activity increase the stability of extracytoplasmic proteins
por: Szczęśniak, Katarzyna, et al.
Publicado: (2023)

Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase
por: Ramsbeck, Daniel, et al.
Publicado: (2021)

Malaria parasite evades mosquito immunity by glutaminyl cyclase–mediated posttranslational protein modification
por: Kolli, Surendra Kumar, et al.
Publicado: (2022)

Editorial: Disease-modifying targets and strategies for Alzheimer's disease and Parkinson's disease
por: Gao, Xiaoya
Publicado: (2023)

Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site
por: Booth, Rachell E, et al.
Publicado: (2004)

Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy
por: Gillis, John Stuart
Publicado: (2006)

Distinct glutaminyl cyclase expression in Edinger–Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Aβ pathology in Alzheimer’s disease
por: Morawski, Markus, et al.
Publicado: (2010)

The promise of multi-omics approaches to discover biological alterations with clinical relevance in Alzheimer’s disease
por: Clark, Christopher, et al.
Publicado: (2022)

Editorial: How does exercise modify the course of Alzheimer's disease?
por: Arciero, Paul J., et al.
Publicado: (2023)

Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease
por: Kanemitsu, Naotoshi, et al.
Publicado: (2021)

Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions
por: Tobeh, Nour S., et al.
Publicado: (2023)

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
por: Scheltens, Philip, et al.
Publicado: (2018)

Linked Production of Pyroglutamate-Modified Proteins via Self-Cleavage of Fusion Tags with TEV Protease and Autonomous N-Terminal Cyclization with Glutaminyl Cyclase In Vivo
por: Shih, Yan-Ping, et al.
Publicado: (2014)

Loop diuretics association with Alzheimer’s disease risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

G-quadruplexes and associated proteins in aging and Alzheimer’s disease
por: Vijay Kumar, M. J., et al.
Publicado: (2023)

Editorial: Molecular mechanisms of Alzheimer’s disease: From top to bottom
por: Mello-Carpes, Pâmela B., et al.
Publicado: (2022)

Neuropathology of Aging in Cats and its Similarities to Human Alzheimer’s Disease
por: Sordo, Lorena, et al.
Publicado: (2021)

Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer’s Disease
por: Cox, MaKayla F., et al.
Publicado: (2022)

Amyloid-β in Alzheimer’s disease – front and centre after all?
por: Weglinski, Caroline, et al.
Publicado: (2023)

The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
por: Hunsberger, Holly C., et al.
Publicado: (2019)

Sex Differences in Large Artery Stiffness: Implications for Cerebrovascular Dysfunction and Alzheimer’s Disease
por: Kehmeier, Mackenzie N., et al.
Publicado: (2021)

Iron chelators as a therapeutic option for Alzheimer’s disease—A mini-review
por: Schreiner, Oliver Daniel, et al.
Publicado: (2023)

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2018)

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
por: Lues, Inge, et al.
Publicado: (2015)

Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis
por: Taudte, Nadine, et al.
Publicado: (2021)

Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease
por: Yu, Weiwei, et al.
Publicado: (2021)

Impact of alcohol-induced intestinal microbiota dysbiosis in a rodent model of Alzheimer’s disease
por: Frausto, Dulce M., et al.
Publicado: (2022)

Highlighting the value of Alzheimer’s disease-focused registries: lessons learned from cancer surveillance
por: Miller, Margaret C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m1ghn4ujb0oipok3o8aju5q52m